Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.

Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y.

Int J Urol. 2019 May 5. doi: 10.1111/iju.14009. [Epub ahead of print]

PMID:
31055879
2.

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer.

Sakamoto S, Maimaiti M, Xu M, Kamada S, Yamada Y, Kitoh H, Matsumoto H, Takeuchi N, Higuchi K, Uchida HA, Komiya A, Nagata M, Nakatsu H, Matsuyama H, Akakura K, Ichikawa T.

J Clin Med. 2019 Apr 11;8(4). pii: E489. doi: 10.3390/jcm8040489.

3.

Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma.

Kasuya G, Tsuji H, Nomiya T, Makishima H, Haruyama Y, Kobashi G, Hayashi K, Ebner DK, Omatsu T, Kishimoto R, Yasuda S, Igarashi T, Oya M, Akakura K, Suzuki H, Ichikawa T, Shimazaki J, Kamada T; Working Group for Genitourinary Tumors.

Oncotarget. 2019 Jan 1;10(1):76-81. doi: 10.18632/oncotarget.26539. eCollection 2019 Jan 1.

4.

Chronological changes in epidemiological characteristics of lower urinary tract urolithiasis in Japan.

Sakamoto S, Miyazawa K, Yasui T, Iguchi T, Fujita M, Nishimatsu H, Masaki T, Hasegawa T, Hibi H, Arakawa T, Ando R, Kato Y, Ishito N, Yamaguchi S, Takazawa R, Tsujihata M, Taguchi M, Akakura K, Hata A, Ichikawa T.

Int J Urol. 2019 Jan;26(1):96-101. doi: 10.1111/iju.13817. Epub 2018 Oct 11.

PMID:
30308705
5.

Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma.

Kasuya G, Tsuji H, Nomiya T, Makishima H, Haruyama Y, Kobashi G, Ebner DK, Hayashi K, Omatsu T, Kishimoto R, Yasuda S, Igarashi T, Oya M, Akakura K, Suzuki H, Ichikawa T, Shimazaki J, Kamada T; Working Group for Genitourinary Tumors.

Cancer Sci. 2018 Sep;109(9):2873-2880. doi: 10.1111/cas.13727. Epub 2018 Sep 1.

6.

Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy.

Yamada Y, Sakamoto S, Amiya Y, Sasaki M, Shima T, Komiya A, Suzuki N, Akakura K, Ichikawa T, Nakatsu H.

Asian J Androl. 2018 Sep-Oct;20(5):432-437. doi: 10.4103/aja.aja_24_18.

7.

Chronological changes in the epidemiological characteristics of upper urinary tract urolithiasis in Japan.

Sakamoto S, Miyazawa K, Yasui T, Iguchi T, Fujita M, Nishimatsu H, Masaki T, Hasegawa T, Hibi H, Arakawa T, Ando R, Kato Y, Ishito N, Yamaguchi S, Takazawa R, Tsujihata M, Matsuda T, Akakura K, Hata A, Ichikawa T.

Int J Urol. 2018 Apr;25(4):373-378. doi: 10.1111/iju.13552.

8.

Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.

Takeuchi N, Sakamoto S, Nishiyama A, Horikoshi T, Yamada Y, Iizuka J, Maimaiti M, Imamura Y, Kawamura K, Imamoto T, Komiya A, Ikehara Y, Akakura K, Ichikawa T.

Clin Genitourin Cancer. 2018 Aug;16(4):e817-e829. doi: 10.1016/j.clgc.2018.02.011. Epub 2018 Feb 24.

PMID:
29576444
9.

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling.

Hirata Y, Morino K, Akakura K, Higano CS, Aihara K.

Sci Rep. 2018 Feb 8;8(1):2673. doi: 10.1038/s41598-018-20788-1.

10.

Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.

Takei A, Sakamoto S, Wakai K, Tamura T, Imamura Y, Xu M, Maimaiti M, Kawamura K, Imamoto T, Komiya A, Akakura K, Ichikawa T.

Int J Urol. 2018 Apr;25(4):352-358. doi: 10.1111/iju.13521. Epub 2018 Jan 11.

11.

Significant prognostic difference between Grade Group 4 and 5 in the 2014 International Society of Urological Pathology Grading System for High Grade Prostate Cancer with Bone Metastasis.

Yamada Y, Sakamoto S, Shimazaki J, Sugiura M, Amiya Y, Sasaki M, Shima T, Komiya A, Suzuki N, Akakura K, Ichikawa T, Nakatsu H.

Prostate Int. 2017 Dec;5(4):143-148. doi: 10.1016/j.prnil.2017.03.001. Epub 2017 Mar 16.

12.

Significance of prostate-specific antigen kinetics after three-dimensional conformal radiotherapy with androgen deprivation therapy in patients with localized prostate cancer.

Fukuokaya W, Kim S, Natsuyama T, Matsuzaki K, Shiomi H, Kitoh H, Utsumi N, Kurosaki H, Inoue M, Akakura K.

Int J Clin Oncol. 2018 Apr;23(2):361-367. doi: 10.1007/s10147-017-1216-9. Epub 2017 Nov 18.

PMID:
29151227
13.

Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy.

Kasuya G, Ishikawa H, Tsuji H, Haruyama Y, Kobashi G, Ebner DK, Akakura K, Suzuki H, Ichikawa T, Shimazaki J, Makishima H, Nomiya T, Kamada T, Tsujii H; Working Group for Genitourinary Tumors.

Cancer Sci. 2017 Dec;108(12):2422-2429. doi: 10.1111/cas.13402. Epub 2017 Nov 3.

14.

Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.

Yamamoto S, Sakamoto S, Minhui X, Tamura T, Otsuka K, Sato K, Maimaiti M, Kamada S, Takei A, Fuse M, Kawamura K, Imamoto T, Komiya A, Akakura K, Ichikawa T.

Clin Genitourin Cancer. 2017 Dec;15(6):e1107-e1115. doi: 10.1016/j.clgc.2017.07.023. Epub 2017 Aug 3.

PMID:
28882738
15.

Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer.

Maruyama K, Tsuji H, Nomiya T, Katoh H, Ishikawa H, Kamada T, Wakatsuki M, Akakura K, Shimazaki J, Aoyama H, Tsujii H; Working Group for Genitourinary Tumors.

J Radiat Res. 2017 Mar 1;58(2):260-266. doi: 10.1093/jrr/rrw122.

16.

The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial.

Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y.

Jpn J Clin Oncol. 2017 Mar 1;47(3):247-251. doi: 10.1093/jjco/hyw193.

PMID:
28042138
17.

Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.

Kasuya G, Ishikawa H, Tsuji H, Nomiya T, Makishima H, Kamada T, Akakura K, Suzuki H, Shimazaki J, Haruyama Y, Kobashi G, Tsujii H; Working Group for Genitourinary Tumors.

Cancer. 2016 Oct 15;122(20):3225-3231. doi: 10.1002/cncr.30050. Epub 2016 Jun 28.

18.

[Intermittent hormone therapy].

Akakura K.

Nihon Rinsho. 2016 May 20;74 Suppl 3:595-9. Japanese. No abstract available.

PMID:
27344800
19.

[Hormonal therapy for advanced prostate cancer: current status and issues].

Akakura K.

Nihon Rinsho. 2016 Jan;74(1):124-8. Japanese.

PMID:
26793892
20.

[REITER'S SYNDROME FOLLOWING INTRAVASICAL BCG THERAPY FOR UROTHELIAL CARCINOMA. SUMMARY OF CASE REPORTS OVER THE PAST 13 YEARS IN JAPAN, INCLUDING OUR CURRENT 6 CASES].

Koike M, Natsuyama T, Matsuzaki K, Yokota E, Shiozawa S, Chiba K, Akakura K.

Nihon Hinyokika Gakkai Zasshi. 2015 Oct;106(4):238-42. Japanese.

PMID:
26717781

Supplemental Content

Loading ...
Support Center